As the therapeutic landscape for chronic lymphocytic leukemia (CLL) continues to expand, biological predictors of response to therapy are becoming increasingly important, according to a recent review.
The immunoglobulin heavy chain (IGHV) gene is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT). The authors note that it is critical that providers understand how mutational status is determined, as well as the limitations of testing. They describe the details of IGHV mutational status testing, highlighting the best way to interpret this information and apply it to care.
Crombie J, Davids M. IGHV mutational status testing in chronic lymphocytic leukemia. [Published online ahead of print June 7, 2017]. Am J Hematol. doi:10.1002/ajh.24808.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al